Outcomes associated with combined antiplatelet and anticoagulant therapy

Chest

Volumn 133, Issue 4, 2008, Pages 948-954

  Johnson, Samuel G ^a   Rogers, Kristina ^a   Delate, Thomas ^a   Witt, Daniel M ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

Anticoagulation; Antiplatelet; Aspirin; Pharmacy; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; CLOPIDOGREL; DIPYRIDAMOLE; WARFARIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; COMBINATION CHEMOTHERAPY; DEATH; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHARMACOEPIDEMIOLOGY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOSIS; TREATMENT OUTCOME;

EID: 42149144098     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-2627     Document Type: Article

References (32)

1. Larson RJ, Fisher ES. Should aspirin be continued in patients started on warfarin: a systematic review and meta-analysis. J Gen Intern Med 2004; 19:879-886
2. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. Circulation 2007; 50:e90-e92
3. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28:1614-1617
4. Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease. Chest 2004; 126: 513S-548S
5. Bertrand ME, Rupprecht HJ, Urban P, et al. CLASSICS Investigators: double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102:624-629
6. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002; 324:71-86
7. Goldhaber SZ, Manson JE, Stampfer MJ, et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. Lancet 1992; 340:143-145
8. SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular isehaemic events. Lancet 1991; 338:1345-1349
9. Farrell B, Godwin J, Richards S, et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54:1044-1054
10. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325:1261-1266
11. Colwell JA, American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2004; 27(suppl):S72-S73
12. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167:1414-1419
13. The Joint Commission. http://www.jointcommission.org/PatientSafety/ NationalPatientSafetyGoals/08_amb_npsgs.htm. Accessed January 30, 2008
14. Johnson SG, Witt DM, Eddy TR, et al. Warfarin and antiplatelet combination use among commercially insured patients enrolled in an anticoagulation management service. Chest 2007; 131:1500-1507
15. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-245
16. Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease: native and prosthetic. Chest 2004; 126;457S-482S
17. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115:2689-2696
18. Shireman TI, Howard PA, Kresowik TF, et al. Combined auticoagulant- antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004; 35:2362-2367
19. Buresly K, Eisenberg MJ, Zhang X, et al. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 2005; 165:784-789
20. van Es RF, Jonker JJ, Verheugt FW, et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002; 360:109-113
21. Brouwer MA, van den Bergh PJ, Aengevaeren WR, et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the antithrombotics in the prevention of reocclusion in coronary thrombolysis (APRICOT-2 Trial). Circulation 2002; 106:659-665
22. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969-974
23. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol 2001; 37:475-484
24. Lechat P, Lardoux H, Mallet A, et al. Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation: a randomized trial. Cerebrovasc Dis 2001; 12:245-252
25. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348:633-638
26. Gullov AL, Koefoed BG, Petersen P, et al. Fixed mini-dose warfarin and aspirin alone and in combination versus adjusted-dose warfarin for stroke prevention in atrial fibrillation. Arch Intern Med 1998; 158:633-638
27. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin k antagonists. Chest 2004; 126: 204S-233S
28. Landefeld CS, Goldman OL. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87:144-152
29. Steffensen F, Kristensen K, Ejlersen E, et al. Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. J Intern Med 1997; 242: 497-503
30. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105:91-99
31. Witt DM, Sadler MA, Shanahan RL, et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005; 127:1515-1522
32. Rothberg MB, Celestin C, Fiore LD, et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005; 143:241-250